EMA does not limit the use of AstraZeneca according to age group

European Bars Agency (EMA) said today after a new study that the benefits of the anti vaccine CO V ID-19 AstraZeneca grew by age and continued to exceed the risks.

“EMA has recommended continuing management of the second dose of the AstraZeneca vaccine between four and 12 weeks after first management, in line with product information”, the European regulator said in a statement, the ATS reported.

“Bilanci profitable-dancing vaccine AstraZeneca remains positive for adults in all age groups”, she added.

In its new assessment, the EMA reiterated that AstraZeneca's benefits exceed the risks, stressing that there are <x0 national authorities that should consider other factors and the best use of vaccine”